Draft monograph: Cagrilintide — disposition

§3Disposition and amendments

§3.1Disposition table

Table 1. Every submission with its disposition. Each row links to the submission in full.

§3.2Summary by disposition

Table 2. Counts by disposition, with the meaning of each.

§3.3Resulting amendments

1. The pharmacokinetic section does not connect half-life to the dosing schedule — arising from DRAFT-CAGRILINTIDE/007. The pharmacokinetic section now states approximate time to steady state alongside the half-life and dosing interval, with the assumption of first-order elimination stated, and records where the assumption is not supported for this compound.
2. The monograph does not tell a reader that a stated mass may be substantially counter-ion and water — arising from DRAFT-CAGRILINTIDE/013. The monograph now states, at the point where vial contents are first mentioned, that a mass figure is uninterpretable unless it states whether it is peptide content or total solids, and cross-references the content standard in the analytical series.
3. The population to which the headline estimate applies is not stated with the estimate — arising from DRAFT-CAGRILINTIDE/008. Every headline estimate now carries a one-line statement of the population in which it was observed, and the full eligibility criteria are reported in the included-studies table rather than only in the source.
4. A near-isobaric analogue is not distinguished by the identity determination described — arising from DRAFT-CAGRILINTIDE/014. The analytical section now states the resolving power required to discriminate the pair, names the pair explicitly, and records that an identity claim made below that resolution is not conformant with the identity standard.
5. What happens when the compound is stopped is not addressed — arising from DRAFT-CAGRILINTIDE/006. Discontinuation trajectory is now an assessed outcome in every monograph where a contributing trial measured it, and a recorded evidence gap in every monograph where none did, so that its absence is visible rather than silent.
6. Registered trials that never reported are absent from the monograph — arising from DRAFT-CAGRILINTIDE/005. The trial list now includes every registered trial the Institute identified, with its reporting status stated, and the monograph reports the proportion of registered trials for which no result has been posted or published.
7. Two factual descriptions of the sponsor's programme are inaccurate — arising from DRAFT-CAGRILINTIDE/004. The trial status now reads as completed at a pre-specified interim analysis, with the analysis identified, and the dose is stated in the unit used in the approved labelling. The submission is identified as an industry submission on its face in accordance with…
8. The analytical section is longer than the clinical assessment it accompanies — arising from DRAFT-CAGRILINTIDE/001. The analytical section is reduced to compound-specific content and cross-references the relevant standards for the general procedure, which shortens it substantially without removing what is not available elsewhere.
9. Evidence for one member of the class is presented as evidence for this compound — arising from DRAFT-CAGRILINTIDE/010. Class-level inferences are now labelled at the point of use, are excluded from the certainty rating for the compound, and are reported in a separate subsection stating which compound the underlying evidence concerns.
10. Effect estimates are given without naming the comparator — arising from DRAFT-CAGRILINTIDE/003. The comparator is now stated in every outcome row, and estimates against different comparators are reported in separate tables with the comparator named in the table caption.
11. The compound is supplied under names the monograph does not list — arising from DRAFT-CAGRILINTIDE/011. The synonym list is extended to include every name the Institute can evidence from a document it holds, each recorded with its source. Names asserted without a supporting document are not added, and the distinction is stated at the head of the list.
12. Adverse event frequencies are given without the denominator or the exposure period — arising from DRAFT-CAGRILINTIDE/002. Every reported frequency now carries the number of participants, the number of events and the exposure period, and comparator-arm figures are reported alongside rather than in a separate table.
13. Trials are described as terminated where they completed as planned — arising from DRAFT-CAGRILINTIDE/009. Trial status now uses a fixed vocabulary defined in the glossary, and where the reason for stopping is not evidenced by a document the Institute holds, the status is recorded as stopped with the reason not established rather than assigned.
14. The monograph should reproduce the approved labelling rather than paraphrase it — arising from DRAFT-CAGRILINTIDE/015. The approved indication and contraindications are now reproduced verbatim from the named authorisation with its version and date, and the posology section reports the labelled schedule and the schedules studied side by side, with the source of each stated.
15. Storage and reconstitution guidance is given without stating what it rests on — arising from DRAFT-CAGRILINTIDE/016. In-use periods now appear only where supported by a cited stability determination on a stated presentation, and elsewhere the monograph records that no in-use stability evidence was identified for this presentation.

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

1. International Organization for Standardization. ISO/IEC 17025:2017 General Requirements for the Competence of Testing and Calibration Laboratories. ISO/IEC Standard 2017;3rd edition. identifier not held by the Institute

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.